ID   PHLP2_HUMAN             Reviewed;        1323 AA.
AC   Q6ZVD8; A1L374; Q9NV17; Q9Y2E3;
DT   07-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   12-APR-2017, entry version 131.
DE   RecName: Full=PH domain leucine-rich repeat-containing protein phosphatase 2;
DE            EC=3.1.3.16;
DE   AltName: Full=PH domain leucine-rich repeat-containing protein phosphatase-like;
DE            Short=PHLPP-like;
GN   Name=PHLPP2; Synonyms=KIAA0931, PHLPPL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [2]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R.;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Retina;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-423 (ISOFORMS 1/2/3), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 639-1323 (ISOFORM 2).
RC   TISSUE=Amygdala, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, AND INTERACTION
RP   WITH AKT1 AND AKT3.
RX   PubMed=17386267; DOI=10.1016/j.molcel.2007.02.017;
RA   Brognard J., Sierecki E., Gao T., Newton A.C.;
RT   "PHLPP and a second isoform, PHLPP2, differentially attenuate the
RT   amplitude of Akt signaling by regulating distinct Akt isoforms.";
RL   Mol. Cell 25:917-931(2007).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH PRKCB.
RX   PubMed=18162466; DOI=10.1074/jbc.M707319200;
RA   Gao T., Brognard J., Newton A.C.;
RT   "The phosphatase PHLPP controls the cellular levels of protein kinase
RT   C.";
RL   J. Biol. Chem. 283:6300-6311(2008).
RN   [9]
RP   INTERACTION WITH FKBP5; AKT2 AND AKT3.
RX   PubMed=19732725; DOI=10.1016/j.ccr.2009.07.016;
RA   Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W.,
RA   Petersen G., Lou Z., Wang L.;
RT   "FKBP51 affects cancer cell response to chemotherapy by negatively
RT   regulating Akt.";
RL   Cancer Cell 16:259-266(2009).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19079341; DOI=10.1038/onc.2008.450;
RA   Liu J., Weiss H.L., Rychahou P., Jackson L.N., Evers B.M., Gao T.;
RT   "Loss of PHLPP expression in colon cancer: role in proliferation and
RT   tumorigenesis.";
RL   Oncogene 28:994-1004(2009).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH STK4.
RX   PubMed=20513427; DOI=10.1016/j.molcel.2010.03.017;
RA   Qiao M., Wang Y., Xu X., Lu J., Dong Y., Tao W., Stein J., Stein G.S.,
RA   Iglehart J.D., Shi Q., Pardee A.B.;
RT   "Mst1 is an interacting protein that mediates PHLPPs' induced
RT   apoptosis.";
RL   Mol. Cell 38:512-523(2010).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH RPS6KB1.
RX   PubMed=21986499; DOI=10.1128/MCB.05799-11;
RA   Liu J., Stevens P.D., Li X., Schmidt M.D., Gao T.;
RT   "PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation
RT   and cell growth.";
RL   Mol. Cell. Biol. 31:4917-4927(2011).
RN   [13]
RP   INTERACTION WITH SLC9A3R1.
RX   PubMed=21804599; DOI=10.1038/onc.2011.324;
RA   Molina J.R., Agarwal N.K., Morales F.C., Hayashi Y., Aldape K.D.,
RA   Cote G., Georgescu M.M.;
RT   "PTEN, NHERF1 and PHLPP form a tumor suppressor network that is
RT   disabled in glioblastoma.";
RL   Oncogene 31:1264-1274(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1210, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, AND MUTAGENESIS OF
RP   PHE-783; ASP-806; PHE-808; GLU-989 AND ASP-1024.
RX   PubMed=24892992; DOI=10.1021/bi500428j;
RA   Sierecki E., Newton A.C.;
RT   "Biochemical characterization of the phosphatase domain of the tumor
RT   suppressor PH domain leucine-rich repeat protein phosphatase.";
RL   Biochemistry 53:3971-3981(2014).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH RAF1.
RX   PubMed=24530606; DOI=10.1053/j.gastro.2014.02.003;
RA   Li X., Stevens P.D., Liu J., Yang H., Wang W., Wang C., Zeng Z.,
RA   Schmidt M.D., Yang M., Lee E.Y., Gao T.;
RT   "PHLPP is a negative regulator of RAF1, which reduces colorectal
RT   cancer cell motility and prevents tumor progression in mice.";
RL   Gastroenterology 146:1301-1310(2014).
CC   -!- FUNCTION: Protein phosphatase involved in regulation of Akt and
CC       PKC signaling. Mediates dephosphorylation in the C-terminal domain
CC       hydrophobic motif of members of the AGC Ser/Thr protein kinase
CC       family; specifically acts on 'Ser-473' of AKT1, 'Ser-660' of PRKCB
CC       isoform beta-II and 'Ser-657' of PRKCA. Akt regulates the balance
CC       between cell survival and apoptosis through a cascade that
CC       primarily alters the function of transcription factors that
CC       regulate pro- and antiapoptotic genes. Dephosphorylation of 'Ser-
CC       473' of Akt triggers apoptosis and decreases cell proliferation.
CC       Also controls the phosphorylation of AKT3. Dephosphorylates STK4
CC       on 'Thr-387' leading to STK4 activation and apoptosis
CC       (PubMed:20513427). Dephosphorylates RPS6KB1 and is involved in
CC       regulation of cap-dependent translation (PubMed:21986499).
CC       Inhibits cancer cell proliferation and may act as a tumor
CC       suppressor. Dephosphorylation of PRKCA and PRKCB leads to their
CC       destabilization and degradation. Dephosphorylates RAF1 inhibiting
CC       its kinase activity (PubMed:24530606).
CC       {ECO:0000269|PubMed:17386267, ECO:0000269|PubMed:18162466,
CC       ECO:0000269|PubMed:19079341, ECO:0000269|PubMed:20513427,
CC       ECO:0000269|PubMed:21986499, ECO:0000269|PubMed:24530606}.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC       {ECO:0000269|PubMed:17386267, ECO:0000269|PubMed:24892992}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC       Note=Binds 2 manganese ions per subunit. Mn(2+) is inhibitory
CC       below pH 8 and activating above pH 8 (PubMed:24892992).
CC       {ECO:0000250, ECO:0000269|PubMed:24892992};
CC   -!- ENZYME REGULATION: Inhibited by AKT1, AKT2 and AKT3. Activated by
CC       oleic acid and arachidonic acid (PubMed:24892992).
CC       {ECO:0000269|PubMed:24892992, ECO:0000305}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=4.13 mM for p-nitrophenyl phosphate;
CC   -!- SUBUNIT: Interacts with AKT1, AKT3 and PRKCB isoform beta-II
CC       (PubMed:17386267, PubMed:18162466, PubMed:19732725). Interacts
CC       with STK4, RPS6KB1, RAF1 (PubMed:20513427, PubMed:21986499,
CC       PubMed:24530606). Interacts with FKBP5; FKBP5 acts as a scaffold
CC       for PHLPP2 and Akt (PubMed:19732725). Interacts with SLC9A3R1;
CC       SLC9A3R1 scaffolds a heterotrimeric complex with PTEN
CC       (PubMed:21804599). {ECO:0000269|PubMed:17386267,
CC       ECO:0000269|PubMed:18162466, ECO:0000269|PubMed:19732725,
CC       ECO:0000269|PubMed:20513427, ECO:0000269|PubMed:21804599,
CC       ECO:0000269|PubMed:21986499, ECO:0000269|PubMed:24530606}.
CC   -!- INTERACTION:
CC       O14745:SLC9A3R1; NbExp=5; IntAct=EBI-2511496, EBI-349787;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane; Peripheral membrane
CC       protein. Nucleus. Note=In colorectal cancer tissue, expression is
CC       concentrated in the cytoplasm and nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q6ZVD8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6ZVD8-2; Sequence=VSP_014056, VSP_014057;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q6ZVD8-3; Sequence=VSP_017265;
CC   -!- TISSUE SPECIFICITY: In colorectal cancer tissue, expression is
CC       highest in the surface epithelium of normal colonic mucosa
CC       adjacent to the cancer tissue but is largely excluded from the
CC       crypt bases. Expression is lost or significantly decreased in 80%
CC       of tested tumors (at protein level).
CC       {ECO:0000269|PubMed:19079341}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA76775.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAA91943.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PHLPP2ID44546ch16q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB023148; BAA76775.2; ALT_INIT; mRNA.
DR   EMBL; BX647823; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC009097; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC129927; AAI29928.1; -; mRNA.
DR   EMBL; AK001854; BAA91943.1; ALT_INIT; mRNA.
DR   EMBL; AK124678; BAC85924.1; -; mRNA.
DR   CCDS; CCDS32479.1; -. [Q6ZVD8-1]
DR   CCDS; CCDS73910.1; -. [Q6ZVD8-3]
DR   RefSeq; NP_001275932.1; NM_001289003.1. [Q6ZVD8-3]
DR   RefSeq; NP_055835.2; NM_015020.3. [Q6ZVD8-1]
DR   UniGene; Hs.709458; -.
DR   ProteinModelPortal; Q6ZVD8; -.
DR   BioGrid; 116674; 14.
DR   DIP; DIP-53556N; -.
DR   IntAct; Q6ZVD8; 16.
DR   MINT; MINT-4781843; -.
DR   STRING; 9606.ENSP00000348611; -.
DR   BindingDB; Q6ZVD8; -.
DR   ChEMBL; CHEMBL1275209; -.
DR   DEPOD; Q6ZVD8; -.
DR   iPTMnet; Q6ZVD8; -.
DR   PhosphoSitePlus; Q6ZVD8; -.
DR   BioMuta; PHLPP2; -.
DR   DMDM; 116242711; -.
DR   MaxQB; Q6ZVD8; -.
DR   PaxDb; Q6ZVD8; -.
DR   PeptideAtlas; Q6ZVD8; -.
DR   PRIDE; Q6ZVD8; -.
DR   DNASU; 23035; -.
DR   Ensembl; ENST00000393524; ENSP00000377159; ENSG00000040199. [Q6ZVD8-3]
DR   Ensembl; ENST00000568954; ENSP00000457991; ENSG00000040199. [Q6ZVD8-1]
DR   GeneID; 23035; -.
DR   KEGG; hsa:23035; -.
DR   UCSC; uc002fax.5; human. [Q6ZVD8-1]
DR   CTD; 23035; -.
DR   DisGeNET; 23035; -.
DR   GeneCards; PHLPP2; -.
DR   H-InvDB; HIX0013215; -.
DR   H-InvDB; HIX0173315; -.
DR   HGNC; HGNC:29149; PHLPP2.
DR   HPA; HPA048598; -.
DR   MIM; 611066; gene.
DR   neXtProt; NX_Q6ZVD8; -.
DR   OpenTargets; ENSG00000040199; -.
DR   PharmGKB; PA165450496; -.
DR   eggNOG; KOG0618; Eukaryota.
DR   eggNOG; KOG0619; Eukaryota.
DR   eggNOG; COG0631; LUCA.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00440000037833; -.
DR   HOGENOM; HOG000115529; -.
DR   InParanoid; Q6ZVD8; -.
DR   KO; K16340; -.
DR   PhylomeDB; Q6ZVD8; -.
DR   TreeFam; TF315993; -.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   SIGNOR; Q6ZVD8; -.
DR   ChiTaRS; PHLPP2; human.
DR   GeneWiki; PHLPPL; -.
DR   GenomeRNAi; 23035; -.
DR   PRO; PR:Q6ZVD8; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000040199; -.
DR   CleanEx; HS_PHLPPL; -.
DR   ExpressionAtlas; Q6ZVD8; baseline and differential.
DR   Genevisible; Q6ZVD8; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0001917; C:photoreceptor inner segment; IBA:GO_Central.
DR   GO; GO:0042622; C:photoreceptor outer segment membrane; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IBA:GO_Central.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0006470; P:protein dephosphorylation; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.60.40.10; -; 1.
DR   Gene3D; 3.80.10.10; -; 5.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001932; PPM-type_phosphatase_dom.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF00481; PP2C; 1.
DR   SMART; SM00369; LRR_TYP; 13.
DR   SMART; SM00332; PP2Cc; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF52058; SSF52058; 3.
DR   SUPFAM; SSF81606; SSF81606; 1.
DR   PROSITE; PS51450; LRR; 18.
DR   PROSITE; PS51746; PPM_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Cytoplasm; Hydrolase;
KW   Leucine-rich repeat; Manganese; Membrane; Metal-binding; Nucleus;
KW   Phosphoprotein; Protein phosphatase; Reference proteome; Repeat;
KW   Tumor suppressor.
FT   CHAIN         1   1323       PH domain leucine-rich repeat-containing
FT                                protein phosphatase 2.
FT                                /FTId=PRO_0000057784.
FT   DOMAIN      150    248       PH.
FT   REPEAT      250    271       LRR 1.
FT   REPEAT      273    296       LRR 2.
FT   REPEAT      300    321       LRR 3.
FT   REPEAT      323    344       LRR 4.
FT   REPEAT      346    368       LRR 5.
FT   REPEAT      369    390       LRR 6.
FT   REPEAT      392    412       LRR 7.
FT   REPEAT      416    439       LRR 8.
FT   REPEAT      440    460       LRR 9.
FT   REPEAT      461    480       LRR 10.
FT   REPEAT      481    502       LRR 11.
FT   REPEAT      503    524       LRR 12.
FT   REPEAT      526    547       LRR 13.
FT   REPEAT      549    570       LRR 14.
FT   REPEAT      571    592       LRR 15.
FT   REPEAT      595    616       LRR 16.
FT   REPEAT      621    644       LRR 17.
FT   REPEAT      645    666       LRR 18.
FT   REPEAT      669    690       LRR 19.
FT   REPEAT      692    713       LRR 20.
FT   REPEAT      714    735       LRR 21.
FT   REPEAT      737    758       LRR 22.
FT   DOMAIN      785   1033       PPM-type phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01082}.
FT   COMPBIAS     40     49       Poly-Thr.
FT   COMPBIAS     50     60       Poly-Ser.
FT   COMPBIAS   1071   1074       Poly-Ser.
FT   METAL       820    820       Manganese 1.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL       820    820       Manganese 2.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL       821    821       Manganese 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL       985    985       Manganese 2.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL      1024   1024       Manganese 2.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   MOD_RES    1210   1210       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     596    662       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10231032}.
FT                                /FTId=VSP_017265.
FT   VAR_SEQ     940    956       DNKVNGVTCCTRMLGCT -> NWVLNQKHLQDFPGEDK
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_014056.
FT   VAR_SEQ     957   1323       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_014057.
FT   MUTAGEN     783    783       F->V: Decreases activity.
FT                                {ECO:0000269|PubMed:24892992}.
FT   MUTAGEN     806    806       D->N: Decreases activity.
FT                                {ECO:0000269|PubMed:24892992}.
FT   MUTAGEN     808    808       F->V: Abolishes activity.
FT                                {ECO:0000269|PubMed:24892992}.
FT   MUTAGEN     989    989       E->Q: Decreases activity.
FT                                {ECO:0000269|PubMed:24892992}.
FT   MUTAGEN    1024   1024       D->N: Decreases activity.
FT                                {ECO:0000269|PubMed:24892992}.
FT   CONFLICT    147    147       R -> C (in Ref. 3; BX647823).
FT                                {ECO:0000305}.
FT   CONFLICT    542    542       V -> L (in Ref. 4). {ECO:0000305}.
FT   CONFLICT    766    766       K -> E (in Ref. 3; BX647823).
FT                                {ECO:0000305}.
FT   CONFLICT    896    896       A -> G (in Ref. 6; BAA91943).
FT                                {ECO:0000305}.
FT   CONFLICT    978    978       E -> G (in Ref. 3; BX647823).
FT                                {ECO:0000305}.
FT   CONFLICT   1016   1016       L -> S (in Ref. 3; BX647823).
FT                                {ECO:0000305}.
FT   CONFLICT   1312   1312       R -> Q (in Ref. 5; AAI29928).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1323 AA;  146751 MW;  04FC8550C2E22A6D CRC64;
     MKRNGSRNCL NRRSRFGSRE RDWLREDVKR GCVYLYGADT TTATTTTTTS SSSSSSSSSS
     DLHLVLCTVE TPASEICAGE GRESLYLQLH GDLVRRLEPT ERPLQIVYDY LSRLGFDDPV
     RIQEEATNPD LGCMIRFYGE KPCHMDRLDR ILLSGIYNVR KGKTQLHKWA ERLVVLCGTC
     LIVSSVKDCQ TGKMHILPLV GGKIEEVKRR QYSLAFSSAG AQAQTYHVSF ETLAEYQRWQ
     RQASKVVSQR ISTVDLSCYS LEEVPEHLFY SQDITYLNLR HNFMQLERPG GLDTLYKFSQ
     LKGLNLSHNK LGLFPILLCE ISTLTELNLS CNGFHDLPSQ IGNLLNLQTL CLDGNFLTTL
     PEELGNLQQL SSLGISFNNF SQIPEVYEKL TMLDRVVMAG NCLEVLNLGV LNRMNHIKHV
     DLRMNHLKTM VIENLEGNKH ITHVDLRDNR LTDLDLSSLC SLEQLHCGRN QLRELTLSGF
     SLRTLYASSN RLTAVNVYPV PSLLTFLDLS RNLLECVPDW ACEAKKIEVL DVSYNLLTEV
     PVRILSSLSL RKLMLGHNHV QNLPTLVEHI PLEVLDLQHN ALTRLPDTLF SKALNLRYLN
     ASANSLESLP SACTGEESLS MLQLLYLTNN LLTDQCIPVL VGHLHLRILH LANNQLQTFP
     ASKLNKLEQL EELNLSGNKL KTIPTTIANC KRLHTLVAHS NNISIFPEIL QLPQIQFVDL
     SCNDLTEILI PEALPATLQD LDLTGNTNLV LEHKTLDIFS HITTLKIDQK PLPTTDSTVT
     STFWSHGLAE MAGQRNKLCV SALAMDSFAE GVGAVYGMFD GDRNEELPRL LQCTMADVLL
     EEVQQSTNDT VFMANTFLVS HRKLGMAGQK LGSSALLCYI RPDTADPASS FSLTVANVGT
     CQAVLCRGGK PVPLSKVFSL EQDPEEAQRV KDQKAIITED NKVNGVTCCT RMLGCTYLYP
     WILPKPHISS TPLTIQDELL ILGNKALWEH LSYTEAVNAV RHVQDPLAAA KKLCTLAQSY
     GCQDNVGAMV VYLNIGEEGC TCEMNGLTLP GPVGFASTTT IKDAPKPATP SSSSGIASEF
     SSEMSTSEVS SEVGSTASDE HNAGGLDTAL LPRPERRCSL HPTPTSGLFQ RQPSSATFSS
     NQSDNGLDSD DDQPVEGVIT NGSKVEVEVD IHCCRGRDLE NSPPLIESSP TLCSEEHARG
     SCFGIRRQNS VNSGMLLPMS KDRMELQKSP STSCLYGKKL SNGSIVPLED SLNLIEVATE
     VPKRKTGYFA APTQMEPEDQ FVVPHDLEEE VKEQMKQHQD SRLEPEPHEE DRTEPPEEFD
     TAL
//
